Certified Hemodialysis Technician Practice Exam 2026 – All-in-One Guide to Exam Success

Lanthanum carbonate is preferred for controlling hyperphosphatemia in patients undergoing dialysis, particularly due to its favorable side effect profile. It is a non-calcium-based phosphate binder, which helps to avoid the complications associated with calcium overload, such as vascular calcification and hypercalcemia. This makes lanthanum carbonate an excellent choice for patients who need to manage their phosphorus levels without the risk of increasing calcium. Additionally, lanthanum carbonate has a low incidence of gastrointestinal side effects compared to some other binders, making it easier for patients to tolerate.

Calcium acetate, while effective, can lead to complications related to calcium build-up. Sevelamer, though a non-calcium option as well, may be associated with gastrointestinal issues like nausea and vomiting. Aluminum hydroxide, while effective in directly binding phosphate, is generally avoided in chronic use due to the risk of aluminum toxicity and associated conditions, such as osteomalacia and neurotoxicity. Thus, lanthanum carbonate stands out as the preferred agent in this context.